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Abstract
Immunocytochemical or molecular assays allow the detection of
single disseminated tumor cells (DTCs) in the bone marrow (BM)
or the peripheral blood in 10% to 60% of breast cancer patients
without signs of metastasis. Results from recently reported studies
suggest that circulating tumor cell (CTC) levels may serve as a
prognostic marker and be used for early assessment of therapeutic
response in patients with metastatic breast cancer. In early stage
breast cancer, however, the impact of CTCs is less well
established than that of DTCs in BM, where several clinical studies
demonstrated that such cells are an independent prognostic factor
at primary diagnosis. The characterization of DTCs/CTCs has
already shed new light on the complex process underlying early
tumor cell dissemination and metastatic progression in cancer
patients. Characterization of DTCs should help to identify novel
targets for biological therapies aimed to prevent metastatic
relapse. In addition, understanding tumor ‘dormancy’ and
identifying metastatic stem cells might result in the development of
new therapeutic concepts.
Introduction
Early spread of tumor cells usually remains undetected in
breast cancer patients even by conventional histopathological
analysis and high-resolution imaging technologies. Therefore,
sensitive immunocytochemical and molecular assays have
been developed that now allow the specific detection of
‘occult’ metastatic tumor cells at the single-cell stage in the
regional lymph nodes, peripheral blood and bone marrow
(BM) before the occurrence of incurable overt metastases.
Early detection of disseminated tumor cells (DTCs) might
help to identify patients in need of additional systemic
therapies after successful surgical resection of the primary
tumor. Although all of these therapies are aimed to prevent
metastatic relapse, the selection of patients is at present
based on their statistical risk of developing tumor recurrence,
without knowing whether they actually harbor any DTCs. This
uncertainty leads to overtreatment of cancer patients with
toxic agents that exert severe side effects. Based on these
considerations, it will not be sufficient to simply characterize
the primary tumor as a therapeutic target, but it will also be
essential to include DTCs in the analysis. This information is
important, in particular, for the design of clinical trials using
biological therapies directed against specific targets.
Sequential screening and monitoring of BM and blood
samples could provide early information about the therapeutic
efficacy of the tested drug against the DTCs. Clearance of
DTCs from BM and/or tumor cells circulating in the blood
could serve as an intermediate endpoint in clinical trials with
anticancer agents. Further molecular and functional
description of these cells will be essential to develop and
select more efficient forms of systemic therapy.
Although the detection of DTCs in lymph nodes is also an
interesting topic, especially in the context of sentinel lymph
node analyses [1-3], this article will focus on the detection,
molecular characterization and clinical relevance of
hematogeneous tumor cell spread as the most crucial step in
breast cancer progression.
Methods for the detection of disseminated
tumor cells
Immunocytochemical staining
Several different assays have been developed to detect
DTCs in breast cancer and other types of carcinomas. One
major approach to identify DTCs is immunocytochemical
staining with monoclonal antibodies against epithelial or
tumor-associated antigens [4-7]. To date, cytokeratins (CKs)
have become the most widely accepted protein markers for
the detection of epithelial tumor cells in mesenchymal tissues
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such as BM, blood or lymph nodes [8-10]; however, different
staining techniques can result in specificity variations [11,12].
Several international organizations have therefore recognized
the need for standardization of the immunocytochemical
assay and for its evaluation in prospective studies [13-15].
Immunocytochemical analysis is usually used in combination
with density gradient centrifugation, immunomagnetic
procedures or size filtration methods to enrich tumor cells
prior to their detection (Figure 1) [16-19]. One way to
improve current detection assays for single tumor cells is to
develop better tumor cell enrichment procedures using
improved density gradients [20] and antibody-coupled
magnetic particles [21-23]. At present it is unclear whether
these new enrichment techniques provide more clinically
relevant information than the standard density gradient
procedure used to isolate the mononuclear cell fraction
(Figure 1).
The use of new automated devices for the microscopic
screening of immunostained slides may help to read slides
more rapidly and to increase reproducibility of the read-out
[21,24-28] (Figure 1). Among the commercially available
automated systems, the CellSearch™ system has gained
considerable attention because it allows automated immuno-
magnetic enrichment and CK staining of blood samples [29].
A recent validation study demonstrated that the recovery rate
of spiked samples averaged between 80% and 82%.
Circulating tumor cells (CTCs) were detected in approxi-
mately 70% of metastatic breast cancer patients. When
analyzing identical samples in different centers, inter-instru-
ment accordance was high. Thus, multicenter studies with
shipment of samples are possible. However, the system is
restricted to the enrichment of epithelial cell adhesion
molecule (EpCAM) positive CTCs and EpCAM expression
can be lost or downregulated as a consequence of an
epithelial to mesenchymal transition [30,31]. In addition, the
number of images that need to be manually checked on the
instrument is rather high and increases with the storage time
of the sample [32], which limits the throughput of CTC
measurements.
PCR approach for the detection of disseminated tumor
cells
A widely used alternative to immunocytochemical assays for
the detection of DTCs comprises molecular detection
procedures. In principle, the nucleic acid in a sample can be
amplified by PCR, so that very small numbers of tumor cells
can be detected in a heterogeneous population of cells.
However, the tumor cells must have changes in DNA or
mRNA expression patterns that distinguish them from the
surrounding hematopoietic cells. At the DNA level, breast
Figure 1
Immunocytochemical detection of disseminated tumor cells (DTCs) in the bone marrow of patients with epithelial tumors. The detection process
begins with Ficoll density gradient centrifugation to isolate mononuclear cells (MNC) and uses cytokeratin (CK) antibodies. The detection of the
stained DTCs can be performed automatically and suspect cells are displayed in an image gallery.Page 3 of 10
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carcinomas are genetically quite heterogeneous, so there is
no universally applicable DNA marker available. Therefore, the
main approach to develop molecular diagnostic assays for
breast carcinomas has focused on RNA markers. A
multimarker approach with a panel of tumor-specific mRNA
markers may improve the sensitivity for the detection of DTCs
oversingle marker assays [33,34].
To date, many transcripts have been evaluated as ‘tumor-
specific’ markers, such as CK18, CK19, CK20, Mucin-1
(MUC1), and carcinoembryonic antigen [35]. However, many
of these transcripts can also be identified by reverse
transcriptase PCR (RT-PCR) in normal BM, blood, and lymph
node tissue [36-38]. Pre-analytical depletion of the disturbing
normal cell fraction (for example, granulocytes that express
CK20) and/or quantitative RT-PCR determinations with well-
defined cut-off values might solve this problem. In addition,
expression of the mRNA marker might be downregulated,
which argues in favor of the use of a multimarker RT-PCR
approach [39].
Enzyme-linked immunospot (ELISPOT) technology
A drawback of both immunocytochemistry and RT-PCR is the
fact that these technologies are usually unable to distinguish
between viable and apoptotic cells. Recently, a new technique
that allows this important discrimination was introduced for
DTC/CTC analyses [40]. This technique was designated
EPISPOT (for epithelial immunospot) and is based on the
secretion or active release of specific marker proteins using an
adaptation of the enzyme-linked immunospot (ELISPOT)
technology. The EPISPOT assay offers the advantages that
only viable tumor cells will be detected and that protein
secretion can be detected at an individual cell level [41]. For
the detection of breast cancer-derived DTCs/CTCs, MUC1
and CK19 were used as marker proteins [42]. MUC1-
secreting CTCs were detected in all metastatic breast cancer
patients analyzed, whereas such cells were not observed in
healthy controls. Moreover, the enumeration of both MUC1-
and CK19-secreting cells allowed the detection of viable
DTCs in the BM of 90% and 54% of breast cancer patients
with and without overt distant metastasis, respectively [42].
These data demonstrate the high specificity and sensitivity of
the new EPISPOT technology, which reveals a unique
fingerprint of single viable tumor cells and opens, therefore, a
new avenue in the understanding of the biology of early
metastatic spread.
Molecular and functional characterization of
disseminated tumor cells
In the past years major efforts have been undertaken to
characterize DTCs by phenotyping and genotyping to identify
biological features that might favor early dissemination. Using
immunological double staining techniques [43] (Figure 2),
different DTC phenotypes were discovered. The presence or
absence of the HER2 proto-oncogene appears to charac-
terize an aggressive subpopulation with regard to invasive
capabilities as well as impaired prognosis [44,45] and has
recently become the focus of potential additional systemic
therapy [46,47]. Furthermore, most DTCs and CTCs do not
express the proliferation antigen Ki-67 and may, therefore, be
resistant to chemotherapy [48,49].
Immunocytochemical assessment of phenotype, however,
has been only one aspect of DTC research. Detailed
molecular descriptions of breast cancer DTCs found in BM at
the genome level revealed a high degree of genetic
heterogeneity [50]. With current techniques, it is possible to
perform genomic analysis even of single cells (Figure 2).
Specifically, genomic aberrations seen in selected areas of
the primary tumors were not seen with the DTCs [51].
Conceivably, the DTCs may have originated from small
subclones within the primary tumor that were not sampled or
they may have undergone significant genetic changes after
disseminating into the BM.
By applying gene expression analysis to primary breast
tumors in relation to the presence or absence of DTCs in BM,
specific gene signatures in primary tumors of patients with
DTCs in BM were observed [52]. These findings challenge
the traditional concept that tumor cells acquire their
metastatic genotype and phenotype late during tumor
development, but rather support the alternative concept that
tumor cells acquire the genetic changes relevant to their
metastatic capacity early in tumorigenesis [53], so that the
metastatic potential of human tumors is encoded in the bulk
of a primary tumor [53,54]. This concept could also explain
the presence of DTCs in BM at early stages of breast cancer.
BM is a homing organ not only for breast cancer DTCs but
also for various epithelial tumors, such as prostate, lung and
colon cancer [16,55,56]. The exact molecular biological
mechanisms, including adhesion molecules and hypoxia, that
allow primary tumor cells to disseminate into BM are under
Available online http://breast-cancer-research.com/content/10/S1/S1
Figure 2
Phenotyping and genotyping of disseminated tumor cells. (a) Three
cytokeratin-positive and HER2-positive disseminated tumor cells
(double staining: green (FITC), cytokeratin; red (TexasRed), HER2). 
(b) Genotyping of a disseminated tumor cell with DNA probes for
chromosome 17 (green) and HER2 (red); HER2 is amplified.investigation [52,57-59]. Interestingly, disseminated tumor
cells express the CXC-chemokine receptor CXCR4 and it
has been shown that metastatic cells may use this
chemokine-mediated mechanism to find their way into the BM
as their preferred reservoir as well as different specific distant
sites, such as lung and liver. After homing, phenotypic
changes must occur to allow DTCs to evolve into solid
metastases. These events require genomic changes such as
cytogenic aberrations as well as phenotypic changes
involving growth factor receptors, proteases, adhesion
molecules and major histocompatibility (MHC) antigens [55].
Half of DTC-positive breast cancer patients will relapse over
a ten year period, while the other half will remain free of
disease [8] (Table 1). Data from animal models suggest that
an important fraction of DTCs might remain in a ‘dormant’
state and never develop into overt metastases. However, the
persistence of DTCs after primary treatment continues to
increase the risk for late metastatic relapse even years after
primary treatment [60]. What exactly characterizes tumor cell
dormancy? Does it describe an entirely non-proliferative state
or does it merely reflect a delicate balance between compe-
ting mechanisms such as proliferation and apoptosis? Our
current knowledge about tumor dormancy as a steady state
of cell metabolism remains limited. Both changes in tumor
cells themselves (for example, additional mutations) as well
as in the surrounding microenvironment (decreased immuno-
surveillance or increased angiogenic potential) could be
involved in the transformation of the quiescent phase into the
dynamic phase of metastasis formation [61-65].
Since we know that the overexpression of the tyrosine kinase
receptor HER2 on DTCs is linked to metastatic relapse
[45,66-68], HER2-mediated signaling could be important
during the transformation from dormant state to an active
growth stage. Other than HER2 related mechanisms, an
increase in p53 mutations [69,70], the accumulation of
genomic imbalances [70,71], and the response to, and
secretion of, stem cell growth factors (epidermal growth
factor, fibroblast growth factor) [42,72,73] could be involved
in the ‘awakening’ of dormant DTCs.
Recent discoveries of new stem cell markers and an
increased interest in the role of so-called breast cancer stem
cells have opened up new avenues of research on DTCs as
well, since it is generally believed that breast cancer stem
cells especially have the potential to disseminate from the
primary tumor to distant sites [42,74-76].
The significant correlation between the presence of DTCs in
BM and metastatic relapse [76] suggests that the ‘stem cells’
of overt metastases might be among those DTCs as meta-
static stem cells. Various findings provide interesting clues:
most DTCs/CTCs are non-proliferating (that is, Ki-67
negative) and resistant to chemotherapy [49,77,78], and
similar characteristics have been postulated for cancer stem
cells. More specifically, Balic and colleagues [79] showed that
micrometastases isolated from the BM of early-stage breast
cancer contain considerable numbers of CD44+CD24-/low
cells, raising the possibility that many, if not the majority, of
early disseminated cancer cells in BM have a putative breast
cancer stem cell phenotype. Furthermore, it appears that
these cells display distinct characteristics, such as increased
angiogenic capacity and the expression of CXCR4 receptors
[79,80], which would facilitate their spread to distant sites.
In summary, the direct analysis of DTCs/CTCs and their
surrounding microenvironment continues to provide new
insights into the complex cascade of breast cancer
metastasis. New methods such as whole genome amplifi-
cation or expression profiling of single tumor cells will provide
more information on the molecular characteristics of early
disseminating tumor cells in breast cancer patients.
Clinical relevance of DTCs and CTCs for
predicting outcome and monitoring therapy
Disseminated tumor cells as a prognostic factor in
primary breast cancer
DTCs in the BM of breast cancer patients are an independent
significant predictor for poor prognosis (Table 2). Conclusive
data on the prognostic relevance of such findings are derived
from recently published studies [4,6,10,22,73,81-83], as well
as a pooled analysis involving 4,703 patients with stage I, II or
III breast cancer. In this study, DTCs were found in 31% of
Breast Cancer Research    Vol 10 Suppl 1 Fehm et al.
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Table 1
Examples of studies examining the prognostic relevance of
disseminated tumor cells identified by immunocytochemistry
in bone marrow of breast cancer patients without overt distant
metastases (stage M0)
Detection 
rate Prognostic  value 
Study (year) [reference] (percent) (no. of patients)
Schlimok et al. (1987) [103] 18 DDFS (155)
Cote et al. (1991) [81] 37 DFS, OS (49)
Harbeck et al. [104] 38 DFS, OSa (100)
Diel et al. (1996) [82] 31 DFSa, OSa (727)
Molino et al. (1997) [105] 31 None (109)
Mansi et al. (1999) [83] 25 DFS, OS (350)
Braun et al. (2000) [10] 36 DFSa, OSa (552)
Gebauer et al. (2001) [4] 42 DFSa, OSa (393)
Gerber et al. (2001) [6] 31 DFSa, OSa (484)
Wiedswang et al. (2003) [22] 13 DDFSa, BCSSa (817)
Braun et al.: pooled analysis  31 DDFSa, OSa (4,703)
(2005) [8]
aConfirmed by multivariate analysis. BCSS, breast cancer-specific
survival; DDFS, distant-DFS; DFS, disease-free survival; OS, overall
survival.the patients [8]. A positive BM finding was a significant
prognostic factor with respect to poor overall survival and
breast-cancer–specific survival with more than twofold
increased hazard ratios. In the multivariate analysis, BM
status was the strongest independent factor for disease-free
and overall survival.
Based on current published recommendations [14], thera-
peutic interventions, risk stratifications and deviations from
internationally accepted adjuvant treatment strategies based
on the presence of DTCs in the BM of patients with newly
diagnosed operable (that is stage I to III) breast cancer
should still be limited to prospective clinical trials until the
clinical value of DTCs for optimization of treatment decisions
has been confirmed in such studies.
Disseminated tumor cell determination during follow-up
In addition to their use as a prognostic factor in breast
cancer, monitoring of BM post-surgery (that is, during and
after systemic adjuvant therapy) might be able to provide
unique information for the clinical management of individual
cancer patients (Table 2). Several studies have indicated that
the presence of DTCs in BM after adjuvant therapy is a
predictor of poor prognosis [44,60,84]. Patients with high-
risk breast cancer (more than three involved axillary lymph
nodes or extensive invasion of cutaneous lymph vessels)
receiving standard taxane or anthracycline containing chemo-
therapy were monitored by BM analysis before and after
adjuvant chemotherapy [84]. The presence of tumor cells
after therapy was associated with an extremely poor prog-
nosis and pointed to a heterogeneous response to treatment.
A recent European pooled analysis involving 696 patients
from three large European academic breast cancer centers
confirmed these findings [85]; 16% of breast cancer patients
had tumor cell persistence in BM. Moreover, in the multi-
variate analysis, allowing for BM status, tumor size, nodal
status and histopathological grading, DTCs were an
independent prognostic factor for subsequent reduced
breast cancer survival followed by nodal status at the time of
primary diagnosis.
The identification of patients at increased risk for recurrence
after completion of adjuvant chemotherapy is an application
of high clinical relevance, since these patients might benefit
from an additional ‘second-line’ treatment, for example,
bisphosphonates or targeted therapies like anti-HER2
approaches. Encouraging results have already been reported
for bisphosphonates.
Bisphosphonates are potent inhibitors of osteoclast-mediated
bone resorption. They are successfully used in conditions of
increased bone turnover such as osteoporosis or bone
metastases. Bisphosphonates inhibit osteoclast precursor
cells, modulate migratory and adhesive characteristics,
induce apoptosis of osteoclasts and influence the micro-
environment [86]. Small trials have been initiated to study the
influence of bisphosphonates on DTCs (for example, MRD-
ZOL-001). DTC-positive primary breast cancer patients are
randomized to zoledronate or observation only after cytotoxic
treatment; results have not been reported yet. A similar study
was performed by Rack and colleagues [87]. All patients
(n = 14) receiving bisphosphonates were DTC negative after
treatment. In contrast, 4 of 14 patients without bisphos-
phonate treatment showed DTC persistence.
HER2-targeted therapy may also be of value for primary
breast cancer patients with HER2-positive DTCs. A human-
ized anti-HER2 monoclonal antibody (trastuzumab) was
recently approved by the Food and Drug Administration
[46,47]. Currently, all patients are stratified to this targeted
therapy by primary tumor analysis only. However, recent
reports have shown that HER2-positive DTCs and CTCs can
also be detected in patients with HER2-negative primary
tumors [31,45,88]. These findings are consistent with
previous data on the high frequency and prognostic rele-
vance of HER2 expression on DTCs in BM [67] and they
suggest that additional patients could benefit from HER2-
directed therapies [88]. Ongoing clinical studies will reveal
whether the HER2 status of DTCs may predict response to
trastuzumab or other HER2-directed therapies.
However, despite these interesting results, therapeutic inter-
ventions based on the presence of DTCs in BM of patients
with no evidence of disease should still be limited to
prospective clinical trials [87].
Circulating tumor cells as a prognostic factor in primary
breast cancer
The clinical relevance of CTCs in primary breast cancer is still
under investigation (Table 2). Depending on the detection
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Table 2
Clinical relevance of disseminated tumor cells in bone marrow
and of circulating tumor cells in blood
Disseminated tumor cells
As a prognostic marker (M0)
As an indicator for secondary adjuvant therapya 
For optimization of ‘secondary’ adjuvant therapy based on the 
genotype and phenoytpe of the disseminated tumor cellsa
Circulating tumor cells
As a prognostic marker (M1)
For therapy monitoring (M1)a
For early therapy response to palliative treatment (M1)a
For reassessment of therapeutic markers by characterization of 
circulating tumor cells (real time biopsy)a
aUnder evaluation. M0, without overt distant metastases; M1, metastatic
disease.technique used, CTCs were revealed in 10% to 60% of
primary breast cancer patients with no clinical signs of overt
metastases [21,26]. Several studies have used RT-PCR
based methods and showed a prognostic impact [89-91].
Nevertheless, the prognostic relevance of CTCs in the blood
of patients with early-stage disease needs to still be
demonstrated in prospective multicenter studies [92].
Circulating tumor cells for monitoring adjuvant therapy
in primary breast cancer
Sequential peripheral blood analyses should be more accep-
table than BM aspirations for therapy monitoring. Therefore,
many research groups are currently assessing the clinical
value of CTCs for therapy monitoring (Table 2). In the
German neoadjuvant trial ‘GeparQuattro’ [93], CTC deter-
minations have been performed before and after primary
systemic chemotherapy. The positivity rate defined as the
detection of one or more CTCs was 22% before treatment
and decreased to 14% after chemotherapy. The correlation
with therapy response has not been reported yet [94].
The aim of the SUCCESS trial [95] is to evaluate the clinical
value of CTCs in an adjuvant setting [96]. So far, CTCs have
been evaluated in 1,767 patients before adjuvant treatment.
The positivity rate defined as the detection of more than one
CTC was 10%. A positive blood count was only correlated to
nodal status. After completion of cytotxic therapy, 7% of
patients showed CTC persistence. Further CTC analyses are
planned after two and five years. At the beginning of 2009, the
first results for the prognostic relevance of CTCs are expected.
Circulating tumor cells as a prognostic and predictive
factor in metastatic breast cancer
The prognostic and predictive value of CTCs in metastatic
breast cancer has been proven by large studies [29,97]
(Table 2). Cristofanilli and colleagues [29] demonstrated in
177 metastatic breast cancer patients that the presence of
five or more tumor cells is associated with worse prognosis.
Interestingly, the CTC count after the first cycle of
chemotherapy indicates poor clinical outcome and the
prognostic impact of increased CTC numbers is also
maintained when repeated examinations during follow-up are
performed [97]. In addition, CTC determinations seem to be
superior over conventional imaging methods for response
evaluation [98]. The clinical utility of these findings are now
being prospectively addressed in a randomized trial, SWOG
S0500, led by the Southwest Oncology group [99].
In this trial only metastatic patients with more than four CTCs
are eligible. The aim of this trial is to determine whether
women with metastatic breast cancer and CTC levels of 5 or
more cells per 7.5 ml of blood after 3 weeks of first-line
chemotherapy show an improved overall survival and
progression-free survival when changing to an alternative
chemotherapy regimen at the next course rather than waiting
for clinical evidence of progressive disease.
Circulating tumor cells for ‘real time biopsy’ at the time
of metastatic disease
The development of metastatic disease is assumed to be a
highly selective process. Only a small portion of tumor cells of
the primary tumor probably have the ability to initiate
metastatic growth in different organ sites. Therefore, the
phenotype of the primary tumor may not necessarily reflect
the phenotype of metastatic disease. There could, therefore,
be a striking potential in reevaluating therapeutic targets on
CTCs, which might enable more individualized and optimized
anti-metastatic therapy in cancer patients. Several small
studies have been reported using CTCs for reevaluation of
HER2 status. Uhr and colleagues [68] reassessed the HER2
status in 31 metastatic patients with CTCs. Of 24 patients
with initially HER2-negative tumors, 9 (38%) had HER2-
positive cells. Four of these nine patients were treated with
Herceptin. Three of these patients showed partial or
complete remission. In the study of Fehm and colleagues
[100], HER2 status was reassessed at the time of metastatic
disease in 21 metastatic breast cancer patients by CTCs.
HER2 was overexpressed in 8 of these 21 initially HER2-
negative patients (38%).
Based on these results, it will be important to design clinical
trials to correlate clinical responses to HER2-targeted therapy
by HER2-positive CTCs in metastatic cancer. Another
important question will be whether hormone receptor status
also changes during disease progression and, therefore,
influences response to palliative endocrine treatment.
Can DTC determination be replaced by CTC analysis?
To date, it is not clear if CTC measurements could replace
the examination of BM. Previously, two immunocytochemical
studies demonstrated statistically significant correlations
between DTC detection in BM and blood but BM was more
frequently positive than blood [49,73]. One possible
explanation is that BM is a homing organ for DTCs, whereas
blood analyses allow only a ‘snap shot’ of tumor cell
dissemination. Recently, it was also reported that detection of
DTCs in BM had superior prognostic significance in compari-
son with CTC measurements in blood when analyzing
patients with metastatic and non-metastatic breast cancer by
a quantitative RT-PCR assay for CK19 and mammaglobin
mRNAs [101]. In line with this, another report using
immunocytochemistry showed that only BM but not blood
analyses provided prognostic information [102]. Currently,
these findings do not support changing from analyzing DTCs
in BM to CTCs from blood, but future studies with improved
detection technologies may help to clarify this issue.
Conclusions and perspectives
Besides the prognostic information derived from the
detection of DTCs in BM and from CTCs, the presence of
these cells may also provide a tool for prediction or
monitoring the efficacy of systemic therapy. The study on
CTCs with the greatest level of evidence performed to date
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measurements might also have particular clinical relevance in
the context of adjuvant systemic therapy.
Prospective clinical studies are now ongoing to evaluate
whether eradication of CTCs in the blood (and also DTCs in
BM) is correlated with a longer disease-free period and
overall survival in the adjuvant setting and if therapy guided by
CTC testing is able to improve the outcome of metastatic
patients. An additional important goal is the possibility of
identifying metastatic tumor specific targets in order to
improve therapy regimens.
The molecular characterization of these cells should allow
further insights into the biology of metastatic dissemination
and, therefore, help to improve treatment strategies.
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